Association of exhaled breath condensate pH with markers of neutrophilic inflammation in bronchoalveolar lavage in young children with cystic fibrosis

2010 ◽  
Vol 11 ◽  
pp. S97-S98
Author(s):  
F. Horak ◽  
T. Eiwegger ◽  
S. Cermak ◽  
P. Fucik ◽  
M. Gona ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Young Children ◽  
Bronchoalveolar Lavage ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Neutrophilic Inflammation ◽  
Breath Condensate

scholarly journals Exhaled Breath Condensate Detects Baseline Reductions in Chloride and Increases in Response to Albuterol in Cystic Fibrosis Patients

2013 ◽  
Vol 7 ◽  
pp. CCRPM.S12882 ◽  
Author(s):  
Courtney M. Wheatley ◽  
Wayne J. Morgan ◽  
Nicholas A. Cassuto ◽  
William T. Foxx-Lupo ◽  
Cori L. Daines ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Exhaled Breath Condensate ◽  
Ionic Composition ◽  
Membrane Conductance ◽  
Pharmacological Therapy ◽  
Exhaled Breath ◽  
Ion Regulation ◽  
Capillary Blood Volume ◽  
Pulmonary Capillary Blood ◽  
Breath Condensate

Impaired ion regulation and dehydration is the primary pathophysiology in cystic fibrosis (CF) lung disease. A potential application of exhaled breath condensate (EBC) collection is to assess airway surface liquid ionic composition at baseline and in response to pharmacological therapy in CF. Our aims were to determine if EBC could detect differences in ion regulation between CF and healthy and measure the effect of the albuterol on EBC ions in these populations. Baseline EBC Cl−, DLCO and SpO2 were lower in CF (n = 16) compared to healthy participants (n = 16). EBC Cl− increased in CF subjects, while there was no change in DLCO or membrane conductance, but a decrease in pulmonary-capillary blood volume in both groups following albuterol. This resulted in an improvement in diffusion at the alveolar-capillary unit, and removal of the baseline difference in SpO2 by 90-minutes in CF subjects. These results demonstrate that EBC detects differences in ion regulation between healthy and CF individuals, and that albuterol mediates increases in Cl− in CF, suggesting that the benefits of albuterol extend beyond simple bronchodilation.

Feasibility of Early Detection of Cystic Fibrosis Acute Pulmonary Exacerbations by Exhaled Breath Condensate Metabolomics: A Pilot Study

2016 ◽  
Vol 16 (2) ◽  
pp. 550-558 ◽  
Author(s):  
Xiaoling Zang ◽  
María Eugenia Monge ◽  
Nael A. McCarty ◽  
Arlene A. Stecenko ◽  
Facundo M. Fernández
Keyword(s):  
Cystic Fibrosis ◽  
Pilot Study ◽  
Early Detection ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Pulmonary Exacerbations ◽  
Breath Condensate

MicroRNA-26a expression in exhaled breath condensate correlates with pulmonary exacerbation in cystic fibrosis

2020 ◽  
Author(s):  
Zuzanna Stachowiak ◽  
Irena Wojsyk-Banaszak ◽  
Katarzyna Jończyk-Potoczna ◽  
Joanna Goździk-Spychalska ◽  
Kamila Sobczak ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Pulmonary Exacerbation ◽  
Breath Condensate

scholarly journals Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis

2001 ◽  
Vol 17 (6) ◽  
pp. 1201-1207 ◽  
Author(s):  
B. Balint ◽  
S.A. Kharitonov ◽  
T. Hanazawa ◽  
L.E. Donnelly ◽  
P.L. Shah ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Investigation of pH of the exhaled breath condensate in inflammatory lung diseases

2005 ◽  
pp. 75-79
Author(s):  
E. Kh. Anaev ◽  
S. N. Avdeev ◽  
A. G. Chuchalin
Keyword(s):  
Cystic Fibrosis ◽  
Healthy Volunteers ◽  
Lung Diseases ◽  
Ph Monitoring ◽  
Exhaled Breath Condensate ◽  
Stable Condition ◽  
Exhaled Breath ◽  
Lung Pathology ◽  
Evaluation And Monitoring ◽  
Breath Condensate

Investigation of inflammatory markers in the exhaled breath condensate (EBC) is a non-invasive method for evaluation and monitoring of bronchopulmonary inflammation. Endogenous oxidative processes in the airways can be evaluated by pH measurement in the EBC. We examined 153 healthy volunteers (of them, 51 smokers) and 615 patients with lung pathology (of them, 131 asthma (BA) patients, 205 COPD patients, 43 patients with bronchiectasis, 72 patients with idiopathic lung fibrosis (ILF), 142 pneumonia patients, and 42 cystic fibrosis patients). EBC was collected with ECoScreen equipment (Erich Jaeger, Germany) using a standardized method. The EBC pH was measured using the f32 PH-meter (Beckman, USA) with a glass microelectrode. The average ECB pH was 6.16 ± 0.52 in BA, 6.35 ± 0.56 in COPD, 6.13 ± 0.46 in bronchiectasis, 5.98 ± 0.30 in ILF, 5.96 ± 0.37 in pneumonia, and 6.35 ± 0.23 in cystic fibrosis. It was significantly lower than in the healthy volunteers (6.97 ± 0.31, р < 0.0001). In patients with exacerbation of BA and COPD ECB pH was considerably lower compared with those in stable condition. A reliable growth of pH was noted in pneumonia patients after treatment of the disease. There was a correlation between ECB pH and severity of fibrotic and inflammatory disorders of lung tissue according to HRCT (r = –0.62, p = 0.01), lung diffusing capacity (r = 0.51, p = 0.01), Tiffeneau index (r = 0.68, p = 0.004) in ILF. Therefore, the ECB pH is a distinct marker of the airway inflammatory severity in lung pathology. The ECB pH monitoring can assess the inflammatory activity and efficacy of anti-inflammatory therapy in lung diseases.

Sign in / Sign up

Export Citation Format

Share Document